Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As I said, I do not really give a shit to convince you are not. You are free to think whatever your bias it. You have done so well on IMUN for the past number of years!
You will think whatever you wish to think. I have told you. Discussion is over.
As I said, Noreen Griffin is not an inventor. That is certainly a lie. As to the uses, those are virtually all known and in the public domain. The patent, although issued, will not stand up in court, IMO.
The patent issued a year or so ago attributed the "invention" to Noreen Griffin and Prof Shen. This is certainly a lie, as Noreen Griffin could never have invented anything. Prof Shen never did any substantial work on LDN. He only worked on MEK. Furthermore, the makes many claims on numerous conditions and diseases, but all of that information has been in the public domain for many years. The patent is fraudulent.
There is virtually nothing about IMUN that is legitimate. That is a complete self delusion.
I really do not give a shit whether you sell or not.
I suspect that the bear movement is now over. No more tax loss selling, double bottom and turn of sentiment.
I agree. I expect the rate of growth of scripts post new label to jump to over 300% per annum. It should be fun to watch what happens to the stock then.
I agree. That is what I said in different words. This week's scripts report is the beginning of that acceleration, motivated by the ADCOM results. Next, the label liberalization will accelerate scripts yet again.
The rate of growth of the script numbers has not, in my opinion, been enough even to justify the revenue growth expectations embedded in the price of the stock. The past script numbers have actually been a restraint on the price of the stock. I believe this script report clearly shows the acceleration in scripts which is the beginning of the hockey stick. This start is driven by the ADCOM results. However, scripts will have to accelerate very dramatically to drive even higher expectations for future revenues. The ultimate revenue scenario will only become clear with the actual label wording and the subsequent scripts boom.
I hope that Canada approves today with a broad label as some expect. It would be for the best of the Canadian socialized health system to do so, and Canada may be that progressive.
but it seems to have traded some in the pre market
At what time does the adcom commence?
Is it certain that Amarin will be closed for trading today?
Please advise.
The selloff from $21 to $16 is quite large. Why do you think this happened? This looks very interesting to me. I do not understand the skeptics out there. Perhaps someone can enlighten me.
I suspect that there will be a rather large short squeeze rally at some point due to the very big short position,....but when?
The price behavior is, indeed, rather crazy. My latest theory about this is that this stock is a favorite target of short selling traders because the stock is heavily owned retail. The logic is, of course, that retail holders are more easily scared out of the stock so a bear raid has greater opportunity for success.
The short interest reported as of two weeks ago was higher than ever, and the stock has even declined since then. This suggests that the shorts have not covered but are continuing to sell. In addition, the anecdotal reports of sentiment are also abnormally negative. Finally, I think that we are in the beginning of tax loss selling, and there are certainly considerable taxable holders in loss positions.
It would seem that this cannot go on much longer, but it is still 7 weeks to the end of the year. Also, the greed of fear & greed is also extremely high, suggesting that a notable correction is coming...not good.
If you are able, I recommend continuing to average down. Next year will be outstanding, I believe.
I have not read the actual filings. I am only skimming the press releases as I think it is all rubbish. However, I think that they are generally alleging that management did not fairly represent the risk of failure of the trials and bad FDA results. Most of these suits will not even get to negotiation as the class will not achieve certification, I think.
I expect that a rational judge will see that the market reaction to the last trial result report was absurd and that the market reaction was just plain wrong. Management cannot be held responsible for irrational market behavior.
I am not worried about them. This is an honest management team with a terrific product and market opportunity. Zynerba is going to destroy GWPH because once Zynerba has any full FDA approval (which is a certainty in my opinion), most doctors will prescribe Zynerba's product for the indications for which GWPH has FDA approval. This will happen because the doctors will know that it is the same molecule but with a superior delivery system that has lower and less risky side effects (i.e. liver risk). The doctors will have virtually zero malpractice risk because IT IS THE SAME MOLECULE! The only risk factor will be that the Zynerba delivery system may require a lower dosage than the GWPH system because Zynerba's trans-dermal delivery is more efficient than the oral system of GWPH.
I think that these various class action suits are having a bigger negative effect on the price of the stock than I previously thought. Today's price slide commenced shortly after yet another class action law suit press release. Personally, I think these suits have no merit but they are likely to be a distraction and annoyance to management.
These suits and likely tax loss selling seems likely to keep the price down until the New Year. Just a theory.
I suspect that yesterday's strong price action was not just Needham. I think that Needham may have triggered some short covering.....a modest short squeeze.
I think that GWPH is a short. I am short.
I suspect that zyne will be fairly quiet until the new year now. We are in the beginning of tax loss selling season. There are plenty of holders with losses and the stock is 85% held retail.
Of course, Noreen Griffin is the one to be blamed. Griffin is the person who articulated the strategy. Griffin is the one who alleged that she would execute the strategy. Griffin is the one who stuffed the Board with morons who were bribed by Griffin and who bought her line of crap. Griffin is the one who failed to achieve anything she ever said that she would do. Griffin is the one who took our money and spent it on herself and other useless and ineffective activities. Griffin is the one who lied to the shareholders continually for seven years. Griffin is the one who drove the stock from $8 to $0.006. Griffin is the one who destroyed the value of your investment: not you...Griffin. Griffin is the one has been a self confessed criminal and crook all along. If anyone of you do not understand these things, then you are seriously self delusional or just plain stupid.
Griffin is the one who should go to jail from criminal fraud, theft, mis-representation, breach of fiduciary duty, and utter insanity.
Zyne trading is following the pattern of yesterday. First, there is some selling on low volume. Then, the bulls creep in and start buying. The final phase (if true to yesterday's pattern) will be a surge in volume as Zyne turns green on the day. This is the sign that the bulls want to see that the bears have no remaining strength. We will see.
Look at the volume pick up once Zyne turned green this afternoon. That is the bulls piling in
It is not completely accurate that zyne has the only therapy for fragile x. OVID has a candidate molecule for fragile x, and I would not under estimate OVID. I suspect that ASD is the even bigger deal for zyne.
It seems likely to me that there has been some serious shorting of zyne in this recent event. That should generate some helpful buying to the price recovery I expect.
Today looks like the turn. The volume is low. There are no more sellers. The buyers are scared but they are creeping back and pushing up the stock. This will accelerate, I suspect, and push the stock up to some new and stable level. I doubt that that level is the previous $11.3. I think more like $9.5 or $10. Serious damage has been done, and OVID did report a competitive product. Also, Zyne has to find new shareholders to replace all of the poor slobs who got shaken out. This has been a very painful interlude for us, the longs. Next year should be very good, IMO. Fragile X and ASD are very big things, and Zyne will have important therapeutic effect to report for both of them, I believe.
Well, not really unbelievable. OVID's report yesterday now means that there are three competitors in the DEE space all with products that are basically competitive. GWPH with hemp derived CBD, Zyne with synthetic CBD and OVID with its proprietary molecule. OVID has the smallest market cap. So, it goes up, and GWPH and Zyne go down. However, Zyne has other things going for it which will support its recovery in due course. These are 1) synthetic CBD (pure, low cost), 2) FX, 3) ASD and 4) 22Q. Zyne is still the lead horse in this race, I believe.
The market has been selling GWPH for a time now. This seemed to accelerate with OVID's press release yesterday. My theory is that the market is now realizing that GWPH is seriously over valued. I think it goes substantially lower. OVID and ZYNE go higher. JMO, as they say.
I suppose that the bulls need to some build confidence after this utter and bizarre disaster. This afternoon may be the beginning sign of confidence. Also, as the bulls contemplate the Tuesday Laudenthal meeting, then Monday may give them strength. That makes sense to me, but I am not a trader.
You do realize, I expect, that GWPH has a $4.5 Billion market cap with only one product for two fairly rare epilepsies. Every one of the four indications which Zyne is targeting is much, much larger than GWPH's indication. Now, mind you, I think GWPH is significantly over valued. That may come from having been first, but it is sometimes said that being second can be much better than being first because it allows one to observe the errors of being first. I think GWPH will get smaller, and Zyne will get much, much bigger.
President William McKinley was my first cousin, thrice removed. That just means that he was a first cousin to my great great grandfather. The President had no direct descendants.
This just posted on StockTwits:
IR said to me today that they will clear the air at the laden meeting on tuesday. Holding on for a big gain for that one. Good luck shorts.
As I expected: this will slaughter the shorts!
Absolutely NOT! My family is outraged.
In my opinion, the stock should have gone to $17 or more on the report of these results because the results proved that the transdermal delivery system is safe and effective. Given the already proven "approvability" by the FDA of medical CBD use (GWPH), plus the superiority of medicinal grade, pure, synthetic Zyne CBD, plus the improved safety profile of transdermal delivery, …. the probability of Zyne's DEE product being approved and commercialized has increased very substantially. Furthermore, the probability of all of the other targeted Zyne indications has also improved considerably. The stock should reasonably have gone to $17 or even $20, and certainly will, once this insane confusion is put behind us.
The company will present next Tuesday at Laudenburg, Thalman and I expect that all of this silly discussion of AE's and SAE's will be fully clarified to the satisfaction of even the most moronic short seller.
BUY, BUY, BUY!
I can no longer hold my tongue. This company is a table pounding, screaming buy. That is my opinion. The results reported show that the delivery system works (better than GWPH) with totally safe results. The approval of the product is basically a layup from here. GWPH has a market cap of $4.5 billion and it has more serious side effects that are gastro-intestinal because their product is ingested. It is highly likely that once approved, Zyne's product will actually take share from GWPH. In addition, Zyne's targeted indications are all supported with strong historical and anecdotal information which virtually guarantees effectiveness and safety is already proven. In the end, it is Zyne that will be worth billions, and billions more than GWPH, and GWPH may well turn into a short sale in a couple of years.
The current price action is pure hysteria motivated by ignorance, fear, margin calls and stop losses.
BUY, BUY, BUY!
I am confident that the management of Amarin is well aware of the limited supply of anchovies or other fish that can supply EPA. As you probably know, these fish do not produce EPA, they ingest it from smaller feedstock. This primary feedstock can likely be farmed, or EPA will likely be synthetically produced to meet demand. That will take some time, but I am confident that Amarin is working on this supply problem diligently.
This company is crap. They have over $100 million in net debt, and a lame and pathetic marketing capability. You might think the stock is cheap with a $30 million equity cap, but the real cap including debt is about $150 million. Furthermore, the net debt has gone up, not down. Pathetic management.
I would short it, but I don't do shorting. I sold my small long.
so what? Let them play. It means nothing, IMO.
What does this mean? "Played with" Who is doing what for what purposes? I think that there is a lot of exaggeration and paranoia about market manipulators. I doubt most of it. The volatility is just human emotion which is over reaction to fear and greed.
The delay of results to September is certainly worrying, but does it mean weak results? I guess, probably, but not sure. Did the market know something about weak results? Also unsure. An explanation for the delay might be helpful, or might not.
Does anyone have any idea how long it should take for this company to reply to the relatively simple inquiry made by the FDA? Is it really difficult? I should think not.